清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past

医学 前线 免疫疗法 淋巴细胞白血病 肿瘤科 临床试验 重症监护医学 免疫学 内科学 白血病 免疫系统 法学 政治学
作者
Nicholas James Short,Hagop M. Kantarjian
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:10 (5): e382-e388 被引量:26
标识
DOI:10.1016/s2352-3026(23)00064-9
摘要

Summary

Multidrug chemotherapy has historically been the cornerstone of therapy for both children and adults with acute lymphocytic leukaemia. However, in the past decade, several novel immunotherapies have proven to be highly effective in the treatment of acute lymphocytic leukaemia, including the anti-CD22 antibody–drug conjugate inotuzumab ozogamicin, the CD3 × CD19 bispecific antibody blinatumomab, and two CD19-directed chimeric antigen receptor T-cell products. These agents are all approved in the USA as monotherapy for relapsed or refractory B-cell acute lymphocytic leukaemia. However, their use as single agents in the salvage setting might not be taking full advantage of their anti-leukaemia potential, because our ability to cure a patient is likely to be greatest when the most effective therapies are safety integrated into front-line treatment regimens. Several ongoing studies have yielded encouraging data with routine incorporation of inotuzumab ozogamicin or blinatumomab, or both, in patients with newly diagnosed acute lymphocytic leukaemia, and these approaches are emerging as new standards of care. In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combining blinatumomab and a BCR-ABL1 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potential for these novel agents to reduce—or perhaps eliminate—the need for chemotherapy in some subtypes. In this Viewpoint, we review promising data from ongoing clinical trials of novel immunotherapy-based combinations that are being explored in patients with newly diagnosed acute lymphocytic leukaemia. We also discuss the challenges of randomised studies in the rapidly evolving therapeutic landscape and argue for the ability of well designed, non-randomised studies to more rapidly advance the standard of care in acute lymphocytic leukaemia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Aaron完成签到,获得积分10
11秒前
16秒前
23秒前
桐桐的应助被葛力采纳,获得10
31秒前
脑洞疼的应助被矢思然采纳,获得10
31秒前
55秒前
李爱国的应助被搞怪的方盒采纳,获得30
56秒前
1分钟前
1分钟前
1分钟前
1分钟前
烟花的应助被开朗的尔蝶采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
幸福丹蝶完成签到,获得积分10
1分钟前
1分钟前
1分钟前
2分钟前
叫啥好呢完成签到 ,获得积分10
2分钟前
clairewen完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
3分钟前
矢思然发布了新的文献求助10
3分钟前
3分钟前
葛力发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
NN的应助被萧雨墨采纳,获得10
4分钟前
123完成签到 ,获得积分10
4分钟前
4分钟前
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190190
求助须知:如何正确求助?哪些是违规求助? 9577282
关于积分的说明 21852326
捐赠科研通 7788645
什么是DOI,文献DOI怎么找? 3436298
关于科研通互助平台的介绍 2560076
邀请新用户注册赠送积分活动 2482902